Percentage of equity interest in related party entity by related party.

No definition available.

Name:	agen_PercentageOfEquityInterestInRelatedPartyEntityByRelatedParty
Namespace Prefix:	agen_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of transactions with related party during the financial reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3

+ Details

Name:	us-gaap_RelatedPartyTransactionAmountsOfTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=agen_ResearchAndDevelopmentManufacturingServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=agen_ProtagenicTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=agen_ClinicalResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Dr. Jennifer Buell
Related Party Transaction [Line Items]
Related party expenses incurred	$ 200,000
Research and Development Manufacturing Services [Member]
Related Party Transaction [Line Items]
Related party expenses incurred		$ 450,000
Research and Development Manufacturing Services [Member] \| Protagenic Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Total expenses	97,000	$ 150,000	$ 106,000
Clinical Research Services [Member]
Related Party Transaction [Line Items]
Related party expenses incurred	$ 450,000
Dr. Garo H. Armen [Member] \| Protagenic Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Percentage of equity interest in related party entity by related party	10.00%